Two phase 3 trials in EPP
Two multicentre, randomised, double-blind, placebo-controlled trials in adults with EPP tested afamelanotide given as a subcutaneous implant (74 people in the European Union trial, 94 in the US trial). The primary outcome was hours of direct sunlight with no pain. In the US trial, median pain-free sunlight time at 6 months was 69.4 hours versus 40.8 hours on placebo (P = 0.04). In the EU trial, at 9 months it was 6.0 hours versus 0.8 hours (P = 0.005), with fewer phototoxic reactions (77 versus 146; P = 0.04). Quality of life improved in both trials, and adverse events were mostly mild.
- Study type
- Human trial
- Population
- 168 adults with erythropoietic protoporphyria (EU trial n=74; US trial n=94); randomised, double-blind, placebo-controlled.
- Source
- 1 Langendonk et al., 2015
Limitation: Funded by the manufacturer and others.
Limitations in full
Funded by the manufacturer and others. Two trials of moderate size with different lengths and endpoints, in a rare condition. Both NHS Scotland and NHS England decided not to recommend routine use (see the NHS recommendations finding below).